Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 22, 2008

Encorium Axes Merger with Prologue and Begins Restructuring

  • Encorium’s planned $11.75 million take-over of Prologue has been put on hold and instead the companies have decided to form a partnership. In conjunction, Encorium is getting rid of 18% of its U.S. employees.

    Encorium and Prologue report that negotiations relating to a merger could take place at a later date. Encorium was not immediately available to provide background on this cancellation.

    The combination of the companies would have expanded Encorium’s business, which focuses on cardiology and vaccines, to include oncology-related CRO services.

    In June, Encorium offered to pay $13 million for Prologue. Earlier this month, however, Encorium reported amendments to its letter of intent such that the purchase price went down to $11.25 million.

    With regard to its restructuring plans, Encorium says that this is just an initial effort to achieve profitability and that it is investigating other alternatives. The company aims to reach $1 million in annual savings.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »